Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-09
2007-10-09
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S187000
Reexamination Certificate
active
10515127
ABSTRACT:
This invention relates to selective m1 muscarinic agonist, their use or a formulation thereof in the treatment of glaucoma and/or other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans. In addition, the present invention relates to the use of the compounds in the treatment of dementia such as Alzheimer's disease and vascular dementia, depression, attention deficit disorder, sleep disorder, schizophrenia, pain, ischemia, atrophic gastritis, and atony of gastrointestinal tract.
REFERENCES:
patent: 4386098 (1983-05-01), Woltersdorf, Jr.
patent: 4416890 (1983-11-01), Woltersdorf, Jr.
patent: 4426388 (1984-01-01), Woltersdorf, Jr.
patent: 4599353 (1986-07-01), Bito
patent: 4668697 (1987-05-01), Shepard et al.
patent: 4797413 (1989-01-01), Baldwin et al.
patent: 4824857 (1989-04-01), Goh et al.
patent: 4863922 (1989-09-01), Baldwin et al.
patent: 4883819 (1989-11-01), Bito
patent: 5001153 (1991-03-01), Ueno et al.
patent: 5153192 (1992-10-01), Dean et al.
patent: 5240923 (1993-08-01), Dean et al.
patent: 5378703 (1995-01-01), Dean et al.
patent: 5574044 (1996-11-01), Thompson et al.
patent: 5718912 (1998-02-01), Thomspon et al.
patent: 5756508 (1998-05-01), Thompson et al.
patent: 10330377 (1998-12-01), None
patent: WO96/13262 (1996-05-01), None
patent: WO97/16186 (1997-05-01), None
patent: WO97/16192 (1997-05-01), None
patent: WO97/24324 (1997-07-01), None
patent: WO99/32481 (1999-07-01), None
patent: WO 01/27104 (2001-04-01), None
patent: WO01/30348 (2001-05-01), None
Gil, et al., Investigative Opthalmology & Visual Science, “Muscarinic Receptor Subtypes in Human Iris—Ciliary Body Measured by Immunoprecipitation”, (1997), vol. 38 No. 7, pp. 1437-1442.
Ward, et al., J. Med. Chem., 1,2,5-Thiadiazole Analogues of Aceclidine as Potent m1 Muscarinic Agonists, (1998), vol. 41, pp. 379-392.
Sauerbert, et al., Bioorganic & Medicinal Chemistry Letter 8, “Identification of Side Chains on 1,2,5,-Thiadiazole-Azacycles Optimal for Muscarinic M1 Receptor Activation”, (1998), pp. 2897-2902.
Berge, et al., Journal of Pharmaceutical Sciences, “Pharmaceutical Salts”, (1977), vol. 66, No. 1, pp. 1-19.
Jeppesen, et al., J. Med. Chem., 1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.02,6] heptanes as New Potent Muscarinic . . . (1998), vol. 42, pp. 1999-2006.
Robert A. Schumer, Arch. Opthalmol, “The Nerve of Glaucoma”, (1994), vol. 112, pp. 37-44.
Dandona, et al., Invest. Ophthalmol. Vis. Sci., “Selective Effects of Experimental Glaucoma on Axonal Transport by Retinal anglion Cells to the Dorsal Lateral Geniculate Nucleus”, (1991), vol. 32, No. 5, pp. 1593-1599.
Eliel, et al., Stereochemistry of Organic Compounds, (1994), 14:1, pp. 1119-1190.
Bonner, et al., Science, “Identification of a Family of Muscarinic Acetylcholine Receptor Genes”, (1987), vol. 237, pp. 527-532.
Ogidigben Miller J
Sagara Yufu
Yamakawa Takeru
Aulakh Charanjit S.
Ayler Sylvia A.
Krovatin William
Merck & Co Inc.
LandOfFree
Ophthalmic compositions for treating ocular hypertension does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ophthalmic compositions for treating ocular hypertension, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ophthalmic compositions for treating ocular hypertension will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3837069